The global diabetic retinopathy devices market, valued at USD 12.47 billion in 2022, is projected to grow at a robust CAGR of around 30% through 2030, driven by rising diabetes cases and an aging population. Non-proliferative diabetic retinopathy is expected to dominate, while North America will lead regionally, with significant contributions from the APAC region due to its large diabetic population. Key players include F. Hoffmann-La Roche, Novartis, and Regeneron, focusing on innovative treatments and technologies.
The global autism spectrum disorder market is valued at approximately $30 billion in 2023, with a projected CAGR of 4% from 2024 to 2032, driven by improved diagnostic tools and early intervention strategies. North America is expected to dominate the market, while the Asia-Pacific region is anticipated to grow rapidly due to increased awareness and healthcare investments. The antipsychotic drug segment leads the market, addressing severe behavioral symptoms and enhancing patients' quality of life.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.